Vaxcyte, Inc. (PCVX)
63.89
+1.97
(+3.18%)
USD |
NASDAQ |
Nov 06, 16:00
63.88
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte Research and Development Expense (Annual) : 794.31M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 794.31M |
| December 31, 2024 | 476.64M |
| December 31, 2023 | 332.34M |
| December 31, 2022 | 169.45M |
| Date | Value |
|---|---|
| December 31, 2021 | 78.41M |
| December 31, 2020 | 73.56M |
| December 31, 2019 | 45.61M |
| December 31, 2018 | 30.14M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Vir Biotechnology, Inc. | 432.80M |
| Anavex Life Sciences Corp. | 37.59M |
| Revolution Medicines, Inc. | 978.68M |
| Foghorn Therapeutics, Inc. | 82.13M |